MCLEAN, Va., July 26, 2024 /PRNewswire/ -- The Association of Organ Procurement Organizations (AOPO) has been recognized with a Power of Associations Gold Award by the American Society of Association Executives (ASAE) for its successful Historically Black Colleges and Universities (HBCUs) & Organ Procurement Organizations (OPOs) Task Force initiative. Continue Reading ASAE The Power of Associations 2024 Gold Award Recipient Badge "AOPO is honored to receive this recognition from ASAE. Our HBCU-O

CHICAGO, July 26, 2024 /PRNewswire/ -- The Alzheimer's Association is disappointed by today's decision by the European Medicines Agency (EMA) to recommend against allowing Leqembi® to be marketed across the European Union. "The EMA has denied people living with Alzheimer's and their families more time," said Joanne Pike, DrPH, Alzheimer's Association president and CEO. "This decision is out of step with the state of the science, and the decisions of the U.S., Chinese, South Korean, Israeli, Hong

ACOG supports cfDNA testing as a reasonable alternative for fetal RBC testing among alloimmunized patients MENLO PARK, Calif., July 26, 2024 /PRNewswire/ -- BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, is thrilled to announce a new publication that shows cfDNA analysis is highly sensitive and specific for determining fetal antigen genotype as early as 10 weeks gestation. The new study published online in Obstetrics

BRISBANE, Calif.--( BUSINESS WIRE )--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the second quarter ended June 30, 2024, after the market closes on Thursday, August 8, 2024. The Company’s management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call by following registration link

VIENNA, Va.--( BUSINESS WIRE )--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the pricing of a best-efforts offering of 10,845,000 shares of its common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being sold at an offering price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price). All of the shares and Pre-Funded Warrants in

- If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union - A decision on the EU marketing authorization is expected by October 2024 TOKYO, July 26, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that on July 26, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positi

- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care for those with unresectable or metastatic urothelial cancer - Positive opinion is based on Phase 3 EV-302 clinical trial results which showed enfortumab vedotin in combination with pembrolizumab nearly doubled median overall survival compared to platinum-containing chemotherapy1 TOKYO, July 26, 2024 /PRN

STOCKHOLM, July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Commission has granted a full marketing authorization for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). The European Commission has granted a full marketing authorization of Kinpeygo®. The granting of the full approval results in a significantly broader label for patients with primary IgAN, moving fr

Grand Rapids family hosts 40th annual golf outing fundraiser supporting Parent Project Muscular Dystrophy GRAND RAPIDS, Mich., July 26, 2024 /PRNewswire/ -- For 40 years, residents of Grand Rapids, Michigan, have supported the mission of Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), by participating in the annual Friar Fight to End Duchenne Golf Tournament. Created and organized by the Friar family in honor of

SHANGHAI, July 26, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary TopAlliance Biosciences Inc. (TopAlliance Biosciences), announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for t